

The LINC5 Study in Children & Adolescents with Cushing's Disease



LINC5 as a Clinical Research Study

In the LINC5 study, children and adolescent patients with Cushing's disease will receive treatment with osilodrostat, to evaluate how osilodrostat works in the pediatric population.

Who can join the study?

Children and adolescents 6 to 18 years of age with Cushing's disease may qualify to participate in this LINC5 clinical research study and receive osilodrostat treatment.

Total Recruitment: 12 patients

Sponsor: Recordati AG

Please scan below for more information about the study

